Show simple item record

dc.contributor.authorMohan, C.
dc.contributor.authorBharathkumar, H.
dc.contributor.authorBulusu, K.
dc.contributor.authorPandey, V.
dc.contributor.authorRangappa, S.
dc.contributor.authorFuchs, J.
dc.contributor.authorShanmugam, M.
dc.contributor.authorDai, X.
dc.contributor.authorLi, F.
dc.contributor.authorDeivasigamani, A.
dc.contributor.authorHui, K.
dc.contributor.authorKumar, Alan Prem
dc.contributor.authorLobie, P.
dc.contributor.authorBender, A.
dc.contributor.authorBasappa
dc.contributor.authorSethi, G.
dc.contributor.authorRangappa, K.
dc.date.accessioned2017-01-30T13:01:21Z
dc.date.available2017-01-30T13:01:21Z
dc.date.created2015-11-04T04:24:24Z
dc.date.issued2014
dc.identifier.citationMohan, C. and Bharathkumar, H. and Bulusu, K. and Pandey, V. and Rangappa, S. and Fuchs, J. and Shanmugam, M. et al. 2014. Development of a novel azaspirane that targets the Janus Kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. Journal of Biological Chemistry. 289 (49): pp. 34296-34307.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/27821
dc.identifier.doi10.1074/jbc.M114.601104
dc.description.abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates genes involved in cell growth, proliferation, and survival, and given its association with many types of cancers, it has recently emerged as a promising target for therapy. In this work, we present the synthesis of N-substituted azaspirane derivatives and their biological evaluation against hepatocellular carcinoma (HCC) cells (IC50 = 7.3 µM), thereby identifying 2-(1-(4-(2-cyanophenyl)1-benzyl-1Hindol-3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5) undecane (CIMO) as a potent inhibitor of the JAK-STAT pathway with selectivity over normal LO2 cells (IC50<100µM). The lead compound, CIMO, suppresses proliferation of HCC cells and achieves this effect by reducing both constitutive and inducible phosphorylation of JAK1, JAK2, and STAT3. Interestingly, CIMO displayed inhibition of Tyr-705 phosphorylation, which is required for nuclear translocation of STAT3, but it has no effect on Ser-727 phosphorylation. CIMO accumulates cancer cells in the sub-G1 phase and decreases STAT3 in the nucleusand thereby causes down-regulation of genes regulated via STAT3. Suppression of STAT3 phosphorylation by CIMO and knockdown of STAT3 mRNA using siRNA transfection displayed a similar effect on the viability of HCC cells. Furthermore, CIMO significantly decreased the tumor development in an orthotopic HCC mouse model through the modulation of phospho-STAT3, Ki-67, and cleaved caspase-3 in tumor tissues. Thus, CIMO represents a chemically novel and biologically in vitro and in vivo validated compound, which targets the JAKSTAT pathway as a potential cancer treatment.

dc.publisherAmerican Society for Biochemistry and Molecular Biology Inc.
dc.titleDevelopment of a novel azaspirane that targets the Janus Kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo
dc.typeJournal Article
dcterms.source.volume289
dcterms.source.number49
dcterms.source.startPage34296
dcterms.source.endPage34307
dcterms.source.issn0021-9258
dcterms.source.titleJournal of Biological Chemistry
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record